Marc de Garidel, Chairman and CEO of Ipsen, stressed that Russia is a key country for Ipsen from the point of view of future development and opportunities for growth:

We regularly increased the sales in Russia over the last years. However, we needed to expand the business for implementation of the whole set of capabilities. We considered the option to execute a partner agreement with the Russian company, and, as a result, we chose the most efficient way at this stage, having entered into cooperation with ROSTA, which high-tech site we use to launch the manufacturing of our products now.

For David Panikashvili,, President of ROSTA:

Localization of international manufacturing in Russia is a logical and important step on the way of national pharmaceutical industry formation, aimed at increasing of availability of highly efficient and high quality drugs for the people of our country. In addition, it also brings additional jobs for training of the dedicated experts.

The Ambassador of France in Russia, Jean-Maurice Ripert, encouraged the cooperation between the French and Russian companies:

There are few countries, which companies invest and create the manufacturing enterprises in Russia more than the French companies do now, especially in pharmaceutical industry. We are very happy that France was ranked the 4^th by foreign investments in Russia upon the results of 2014.

According to the Manager of Russian representative office of Ipsen, Marina Veldanova:

Partnership with ROSTA – one of the leaders of Russian pharmaceutical market, and launch of local manufacturing of the drug is a result of many years of fruitful work and one more proof of high priority of the Russian market for Ipsen.